An interventional study of Sprint PNS system and Radiofrequency Ablation in Facet Joint Pain, sponsored by Penn State University. Withdrawn at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by Penn State University · Not applicable, Interventional, and Treatment
Difficulty recruiting patients. Study is in close out process.
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 106 studies in Arthralgia with a site in United States — 17 open to participants now, 23 under way, 4 of them phase 3. Arthralgia · United States.
Among the 106 studies in Arthralgia with a site in United States, this one is the 85th largest by enrollment of the 88 interventional ones that give a count, is one of 8 that started in 2026, is one of 46 with no phase, and was the 92nd registered.
277 studies on the registry are indexed under Arthralgia; 54 are open to participants now.
Browse Arthralgia studies →17 of the 106 studies in Arthralgia with a site in United States are open now. Recruiting first, the newest first:
Indiana University · Sites in United States
Ages 18+
PainTEQ, LLC · Sites in United States
Ages 21+
PainTEQ, LLC · Sites in United States
Ages 21+
Weill Medical College of Cornell University · Sites in United States
Ages 18–75
Veterans Medical Research Foundation · Sites in United States
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 35 Arthralgia studies recruiting now, 18 (51%) set no upper age limit and 16 (46%) stop at 75 or younger; 1 takes children under 18; 9 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
106 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 16 · Phase 3 20 · Phase 4 6
First in 2004; this study’s year is marked. 8 started in 2026.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 82 across the 88 interventional studies, 144 across the 18 observational. Of the 67 that completed or were terminated, 24 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 106 have an industry lead sponsor. The 10 most frequent:
Penn State University is the lead sponsor of 271 studies on the registry; 54 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 11 (73%) have results posted.
Penn State University has 1 study filed under Arthralgia — fewer than ten, so there is no comparison to draw.
7 of the studies in Arthralgia with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05703178Phase 3Northwestern UniversityWeb-based Pain Coping Skills Training for Breast Cancer Survivors With AI-Associated Arthralgia | 2026-11-30 |
| NCT05658575Phase 3Olatec Therapeutics, Inc.Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare | 2026-12-31 |
| NCT05621369Sage BionetworksPsorcast Mobile Study | 2027-01-31 |
| NCT04994249Stanford UniversityDiagnostic and Prognostic Biomarkers for High-impact Chronic Pain: Development and Validation | 2027-04-25 |
| NCT07547215PainTEQ, LLCPost-Market Clinical Study Using TRAQ™ for Minimally Invasive Posterior Sacroiliac Joint Fusion | 2027-07 |
Add all 7 to your calendar (.ics) → With an account.
Among the 106 studies in Arthralgia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Radiofrequency ablation of the medial nerve is the current surgical treatment for back pain originating from the facet joints in the spine. However, this procedure causes denervation of spinal muscles. Peripheral nerve stimulation is another treatment for facet joint pain that may not cause damage to the spinal muscles. This study will compare both treatments in terms pain relief and spine biomechanics.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Peripheral nerve stimulation (PNS) is a procedure used to relieve chronic back pain by targeting the nerves responsible for transmitting pain signals from the back to the brain. It is a minimally invasive approach that aims to disrupt the pain signals and provide pain relief.
Device: Sprint PNS system
Radiofrequency ablation (RFA) is the current standard of care for facet joint pain. It is a minimally invasive procedure used to relieve chronic back or neck pain caused by issues with the small joints in the spine called facet joints.
Procedure: Radiofrequency Ablation
Temporary electrical stimulation of the medial nerve with implanted wires and wearable stimulator
Thermal ablation of the medial nerve
Multifidus muscle activity
Muscle contraction quantification via shear wave elastography
Time frame: pre-treatment
Multifidus muscle activity
Muscle contraction quantification via shear wave elastography
Time frame: within two weeks of treatment completion
Multifidus muscle activity
Muscle contraction quantification via shear wave elastography
Time frame: 12 months after pre-treatment measurement
Pain Intensity
Visual Analog Scale, scale range 1 - 10, 10 being worse possible pain.
Time frame: pre-treatment
Pain Intensity
Visual Analog Scale, scale range 1 - 10, 10 being worse possible pain.
Time frame: within two weeks of treatment completion
Pain Intensity
Visual Analog Scale, scale range 1 - 10, 10 being worse possible pain.
Time frame: 12 months after pre-treatment measurement
Oswestry Disability Index
Survey evaluating disability level, 0 - 4 No disability 5 - 14 Mild disability 15 - 24 Moderate disability 25 - 34 Severe disability 35 - 50 Completely disabled
Time frame: pre-treatment
Oswestry Disability Index
Survey evaluating disability level, 0 - 4 No disability 5 - 14 Mild disability 15 - 24 Moderate disability 25 - 34 Severe disability 35 - 50 Completely disabled
Time frame: within two weeks of treatment completion
Oswestry Disability Index
Survey evaluating disability level, 0 - 4 No disability 5 - 14 Mild disability 15 - 24 Moderate disability 25 - 34 Severe disability 35 - 50 Completely disabled
Time frame: 12 months after pre-treatment measurement
PROMIS-29 v2.0
Survey assessing pain intensity using a single 0-10 numeric rating item and seven health domains (physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance)
Time frame: pre-treatment
PROMIS-29 v2.0
Survey assessing pain intensity using a single 0-10 numeric rating item and seven health domains (physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance)
Time frame: within two weeks of treatment completion
PROMIS-29 v2.0
Survey assessing pain intensity using a single 0-10 numeric rating item and seven health domains (physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance)
Time frame: 12 months after pre-treatment measurement
isometric back strength
Measurement of peak force generated by the torso in extension in Newtons
Time frame: pre-treatment
Isometric back strength
Measurement of peak force generated by the torso in extension in Newtons
Time frame: within two weeks of treatment completion
isometric back strength
Measurement of peak force generated by the torso in extension in Newtons
Time frame: 12 months after pre-treatment measurement
Functional Reach
distance between the length of an outstretched arm in a maximal forward reach, 10"/25 cm or greater Low risk of falls, 6"/15cm to 10"/25cm Risk of falling is 2x greater than normal, 6"/15cm or less Risk of falling is 4x greater than normal, Unwilling to reach Risk of falling is 8x greater than normal.
Time frame: pre-treatment
Functional Reach
distance between the length of an outstretched arm in a maximal forward reach, 10"/25 cm or greater Low risk of falls, 6"/15cm to 10"/25cm Risk of falling is 2x greater than normal, 6"/15cm or less Risk of falling is 4x greater than normal, Unwilling to reach Risk of falling is 8x greater than normal.
Time frame: within two weeks of treatment completion
Functional Reach
distance between the length of an outstretched arm in a maximal forward reach, 10"/25 cm or greater Low risk of falls, 6"/15cm to 10"/25cm Risk of falling is 2x greater than normal, 6"/15cm or less Risk of falling is 4x greater than normal, Unwilling to reach Risk of falling is 8x greater than normal.
Time frame: 12 months after pre-treatment measurement
Repetitive Trunk Rotation
Time to complete 20 rotations, seconds, longer times are worse performance.
Time frame: pre-treatment
Repetitive Trunk Rotation
Time to complete 20 rotations, seconds, longer times are worse performance.
Time frame: within two weeks of treatment completion
Repetitive Trunk Rotation
Time to complete 20 rotations, seconds, longer times are worse performance.
Time frame: 12 months after pre-treatment measurement
Repeated Chair Stands
Time to perform 5 repeated chair stands, higher times mean worse outcomes.
Time frame: pre-treatment
Repeated Chair Stands
Time to perform 5 repeated chair stands, higher times mean worse outcomes.
Time frame: within two weeks of treatment completion
Repeated Chair Stands
Time to perform 5 repeated chair stands, higher times mean worse outcomes.
Time frame: 12 months after pre-treatment measurement
Pfirmmann grade
Degeneration of lumbar discs at the treated level, grade 1 - 5, 1 is normal and 5 is completely collapsed disc.
Time frame: pre-treatment
Pfirmmann grade
Degeneration of lumbar discs at the treated level, grade 1 - 5, 1 is normal and 5 is completely collapsed disc.
Time frame: within two weeks of treatment completion
Pfirmmann grade
Degeneration of lumbar discs at the treated level, grade 1 - 5, 1 is normal and 5 is completely collapsed disc.
Time frame: 12 months after pre-treatment measurement
t2-relaxation time
T2 relaxation time of the disc at the treated level. Lower values indicate more degeneration.
Time frame: pre-treatment
t2-relaxation time
T2 relaxation time of the disc at the treated level. Lower values indicate more degeneration.
Time frame: within two weeks of treatment completion
t2-relaxation time
T2 relaxation time of the disc at the treated level. Lower values indicate more degeneration.
Time frame: 12 months after pre-treatment measurement
2-point dixon MRI
Intramuscular fat percentage, higher percentage means worse outcome.
Time frame: pre-treatment
2-point dixon MRI
Intramuscular fat percentage, higher percentage means worse outcome.
Time frame: within two weeks of treatment completion
2-point dixon MRI
Intramuscular fat percentage, higher percentage means worse outcome.
Time frame: 12 months after pre-treatment measurement
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Apr 2026 to primary completion in Apr 2026, 0 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: start Feb 2026 → Apr 2026, primary completion Oct 2026 → Apr 2026 and completion Oct 2027 → Apr 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Difficulty recruiting patients. Study is in close out process.
Difficulty recruiting patients. Study is in close out process.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is withdrawn, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.